New brain cancer drug enters first human safety tests
NCT ID NCT05432375
Summary
This was a small, early-stage study to test the safety and dosing of a new drug called tinostamustine for a type of brain cancer called glioblastoma. It involved 10 adults who had recently finished standard radiation and chemotherapy. The main goal was to find the highest dose patients could tolerate without severe side effects, while also checking if the drug showed any signs of fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Universitario Ramón y Cajal, Madrid, Spain
Madrid, Spain
-
Hospital Universitario Vall d'Hebron, Barcelona, Spain
Barcelona, Spain
-
Kantonsspital
Sankt Gallen, Switzerland
-
South Texas Accelerated Research Therapeutics (START)
Madrid, Spain
-
University Hospital
Zurich, Switzerland
Conditions
Explore the condition pages connected to this study.